Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Josefine Clement Freiberg*, Alexander von Spreckelsen, Naira Khachatryan, Miriam Kolko, Augusto Azuara-Blanco, Gianni Virgili

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of rho kinase inhibitors to placebo or other glaucoma medication in people diagnosed with open-angle glaucoma or ocular hypertension.

Original languageEnglish
Article numberCD013817
JournalCochrane Database of Systematic Reviews
Issue number12
Publication statusPublished - 16 Dec 2020

Bibliographical note

Funding Information:
Thank you to the Cochrane Eyes and Vision (CEV) Information Specialist, who created and will execute the electronic search strategies. We thank Renee F. Wilson from CEV@US for her helpful feedback. We thank the following peer reviewers for their feedback: Renee Bovelle (Howard University) and Anthony King (Spire Nottingham Hospital). This protocol was managed by CEV@US and was signed off for publication by Tianjing Li and Richard Wormald.

Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Copyright 2021 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension'. Together they form a unique fingerprint.

Cite this